


Product Name : SNX631
Cat. No. : PC-49204
CAS No. : 868066-26-6
Molecular Formula : C₂₂H₂₆N₆O₂S
Molecular Weight : 438.550
Target : Cyclin-dependent Kinase (CDK)
Solubility : 10 mM in DMSO



Biological Activity

SNX631 (SNX-631) is a potent, selective inhibitor of **CDK8/19** Mediator kinase with IC₅₀ of 10.3 nM in the NF κB-dependent cell-based assays.

SNX631 is 6 to 10 times more potent than Senexin B in all the assays except for the DiscoverX activesite-dependent competition binding assay.

SNX631 showed synergistic interactions with lapatinib and trastuzumab in a panel of HER2+ BrCa cell lines, overcoming and preventing resistance to HER2-targeting drugs.

Combination of HER2-mAb trastuzumab and SNX631 inhibited STAT1 and STAT3 phosphorylation at S727 and up-regulated tumor suppressor BTG2 in HER2+ BrCa cell lines.

SNX631 partially inhibits growth of xenograft tumors formed by lapatinib-sensitive or -resistant HER2+ breast cancer cells alone, and strongly suppressed by the combination of lapatinib, overcoming lapatinib resistance.

References

Jing Li, et al. *Cells*. 2019 Oct 6;8(10):1208.

Xiaokai Ding, et al. *Proc Natl Acad Sci U S A*. 2022 Aug 9;119(32):e2201073119.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com